YMAB - Y-mAbs Therapeutics GAAP EPS of -$0.63 beats by $0.07 revenue of $12.5M beats by $0.49M
- Y-mAbs Therapeutics press release ( NASDAQ: YMAB ): Q3 GAAP EPS of -$0.63 beats by $0.07 .
- Revenue of $12.5M (+39.4% Y/Y) beats by $0.49M .
- Shares +7.5% .
- Cash position of $114.5 million as of September 30, 2022, anticipated runway into mid-2024.
- FY Guidance : DANYELZA® product revenues of $45-$50 million; Operating expenses of $162-167 million; Total cash burn of $78-83 million; and Cash position sufficient to fund current operations as planned into mid-2024.
For further details see:
Y-mAbs Therapeutics GAAP EPS of -$0.63 beats by $0.07, revenue of $12.5M beats by $0.49M